Cervical Lesions 
 

Have you High Grade CIN2/CIN3 lesions detected?

 

We are trying a new intravaginal drug to treat these pre-cancerous lesions!

 

If you are successfully enrolled, the study will provide colposcopies and if you require a LLETZ procedure, it will be free of charge!

​

Antiva Biosciences is developing the study drug ABI-2280 as a potential new topical treatment for pre-cancerous lesions on the cervix caused by the Human Papillomavirus (HPV). The medication is in the form of a tablet that is inserted into the vagina.

 

To date, the main treatment options for these cervical lesions include surgery or laser ablation (removal) of these pre-cancerous lesions. However, surgery or removal of the lesion can cause complications for pregnancy and therefore is a less desirable treatment for women planning to be pregnant.

 

A safe and effective topical treatment like ABI-2280 would offer a choice for patients wanting a non-surgical treatment option. Currently, there is no approved drug for the treatment of pre-cancerous lesions on the cervix.

 

Your participation in the ABI-2280-303 trial may help us to better understand treatment for pre-cancerous cervical lesions, which could help others in the future.

​

In order to be eligible, you must meet the following criteria:

• Women, aged between 22 to 55

• When examined in our clinic, you are found to have high grade CIN2/CIN3 lesions, and a positive high-risk HPV result.

 

You will be in the ABI-2280-303 trial for approximately 2 weeks and followed for safety for up to 12 weeks. You will need to:

• Attend your visit appointments

• Undergo procedures (including Pelvic Exams and a LLETZ procedure) at various times during the study

• Consent to the collection and testing of your urine, blood and tissue samples